Enzo Biochem Company Profile (NYSE:ENZ)

About Enzo Biochem (NYSE:ENZ)

Enzo Biochem logoEnzo Biochem, Inc. is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company's segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies. It offers a menu of molecular and other clinical laboratory tests or procedures. Enzo Life Sciences manufactures, develops and markets products and tools to clinical research, drug development and bioscience research customers. Enzo Therapeutics is a biopharmaceutical venture that develops multiple approaches in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases. Its products in the development pipeline include a range of assays for detection of various women's health infectious agents, as well as for use in the identification of pathogens for other markets.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical & Diagnostic Laboratories
  • Sub-Industry: N/A
  • Symbol: NYSE:ENZ
  • CUSIP: N/A
  • Web: www.enzo.com
Capitalization:
  • Market Cap: $464.54 million
  • Outstanding Shares: 46,547,000
Average Prices:
  • 50 Day Moving Avg: $10.67
  • 200 Day Moving Avg: $10.22
  • 52 Week Range: $5.21 - $12.04
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 249.50
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $107.8 million
  • Price / Sales: 4.31
  • Book Value: $1.91 per share
  • Price / Book: 5.23
Profitability:
  • EBITDA: $532,000.00
  • Net Margins: -2.32%
  • Return on Equity: -2.83%
  • Return on Assets: -2.32%
Debt:
  • Current Ratio: 5.00%
  • Quick Ratio: 4.61%
Misc:
  • Average Volume: 186,105 shs.
  • Beta: 0.89
  • Short Ratio: 2.45
 

Frequently Asked Questions for Enzo Biochem (NYSE:ENZ)

What is Enzo Biochem's stock symbol?

Enzo Biochem trades on the New York Stock Exchange (NYSE) under the ticker symbol "ENZ."

How were Enzo Biochem's earnings last quarter?

Enzo Biochem, Inc. (NYSE:ENZ) issued its quarterly earnings results on Wednesday, June, 8th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.06) by $0.02. The firm earned $18.16 million during the quarter, compared to analyst estimates of $24.50 million. Enzo Biochem had a negative net margin of 2.32% and a negative return on equity of 2.83%. During the same quarter in the prior year, the business posted ($0.07) earnings per share. View Enzo Biochem's Earnings History.

Who are some of Enzo Biochem's key competitors?

Who are Enzo Biochem's key executives?

Enzo Biochem's management team includes the folowing people:

  • Barry W. Weiner, President, Chief Financial Officer, Principal Accounting Officer, Treasurer, Director
  • Elazar Rabbani Ph.D., Chairman of the Board, Chief Executive Officer, Secretary
  • James M. O'Brien, Executive Vice President - Finance
  • David C. Goldberg, Vice President - Corporate Development, General Manager of Enzo Clinical Labs
  • Dieter Schapfel M.D., Chief Medical Director
  • Bruce A. Hanna Ph.D., Director
  • Gregory M. Bortz, Independent Director
  • Dov Perlysky, Independent Director

How do I buy Enzo Biochem stock?

Shares of Enzo Biochem can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Enzo Biochem's stock price today?

One share of Enzo Biochem stock can currently be purchased for approximately $9.98.


MarketBeat Community Rating for Enzo Biochem (NYSE ENZ)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  59 (Vote Outperform)
Underperform Votes:  76 (Vote Underperform)
Total Votes:  135
MarketBeat's community ratings are surveys of what our community members think about Enzo Biochem and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Enzo Biochem (NYSE:ENZ) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for Enzo Biochem (NYSE:ENZ)
Price Target History for Enzo Biochem (NYSE:ENZ)
Analysts' Ratings History for Enzo Biochem (NYSE:ENZ)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/9/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
(Data available from 10/20/2015 forward)

Earnings

Earnings History for Enzo Biochem (NYSE:ENZ)
Earnings by Quarter for Enzo Biochem (NYSE:ENZ)
Earnings History by Quarter for Enzo Biochem (NYSE ENZ)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/13/2017Q2 2017($0.04)($0.02)$26.10 million$26.26 millionViewN/AView Earnings Details
12/8/2016Q117($0.05)($0.03)$25.90 million$26.28 millionViewN/AView Earnings Details
10/13/2016Q416($0.06)($0.04)$26.00 million$26.60 millionViewN/AView Earnings Details
6/8/2016Q316($0.06)($0.04)$24.50 million$18.16 millionViewN/AView Earnings Details
3/9/2016Q216($0.06)($0.07)$24.43 million$24.60 millionViewN/AView Earnings Details
12/7/2015Q116($0.05)($0.05)$25.00 million$25.18 millionViewN/AView Earnings Details
10/13/2015Q415($0.06)($0.06)$24.60 million$25.70 millionViewListenView Earnings Details
6/9/2015Q315($0.06)($0.07)$24.40 million$23.99 millionViewN/AView Earnings Details
3/12/2015Q215($0.09)($0.09)$24.20 million$23.09 millionViewN/AView Earnings Details
12/9/2014Q114($0.08)($0.08)$24.50 million$24.82 millionViewListenView Earnings Details
10/9/2014Q4 2014($0.07)($0.06)$23.60 million$24.91 millionViewListenView Earnings Details
6/9/2014Q314($0.09)($0.05)$22.80 million$24.00 millionViewN/AView Earnings Details
3/11/2014Q2($0.08)($0.09)$22.00 million$22.93 millionViewListenView Earnings Details
12/11/2013Q1($0.06)($0.07)ViewListenView Earnings Details
10/16/2013Q413($0.08)$22.00 million$23.30 millionViewListenView Earnings Details
6/10/2013Q3 2013($0.15)$22.20 million$22.60 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Enzo Biochem (NYSE:ENZ)
Current Year EPS Consensus Estimate: $-0.02 EPS
Next Year EPS Consensus Estimate: $0.04 EPS

Dividends

Dividend History for Enzo Biochem (NYSE:ENZ)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Enzo Biochem (NYSE:ENZ)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Enzo Biochem (NYSE:ENZ)
Latest Headlines for Enzo Biochem (NYSE:ENZ)
Source:
DateHeadline
thestreet.com logoEnzo Biochem Enters Oversold Territory (ENZ)
www.thestreet.com - October 17 at 8:32 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 6:52 PM
finance.yahoo.com logoEarnings Review and Free Research Report: Enzo Biochem’s Q4 and Annual Top-line Rise on a Y-o-Y Basis
finance.yahoo.com - October 10 at 4:04 PM
americanbankingnews.com logoEnzo Biochem, Inc. (ENZ) Downgraded by TheStreet
www.americanbankingnews.com - October 2 at 5:08 PM
finance.yahoo.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 28, 2017
finance.yahoo.com - October 2 at 2:58 PM
finance.yahoo.com logoEnzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017
finance.yahoo.com - October 2 at 2:58 PM
finance.yahoo.com logoEdited Transcript of ENZ earnings conference call or presentation 28-Sep-17 12:30pm GMT
finance.yahoo.com - October 2 at 2:58 PM
finance.yahoo.com logoEnzo Biochem, Inc. :ENZ-US: Earnings Analysis: Q4, 2017 By the Numbers : September 29, 2017
finance.yahoo.com - October 2 at 2:58 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : October 2, 2017
finance.yahoo.com - October 2 at 2:58 PM
benzinga.com logoEarnings Scheduled For September 27, 2017 - Benzinga
www.benzinga.com - September 29 at 2:52 PM
nasdaq.com logoEnzo Biochem Inc (ENZ) Files 10-K for the Fiscal Year Ended on July 31, 2017 - Nasdaq
www.nasdaq.com - September 29 at 2:52 PM
msn.com logoEnzo Biochem's (ENZ) Q4 2017 Results - Earnings Call Transcript
www.msn.com - September 28 at 5:51 PM
baystreet.ca logoInvestor Network: Enzo Biochem, Inc. to Host Earnings Call
www.baystreet.ca - September 28 at 9:44 AM
businesswire.com logoEnzo Biochem Reports Increase in Revenues and Profitable Fourth Quarter
www.businesswire.com - September 27 at 6:33 PM
businesswire.com logoEnzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8 ... - Business Wire (press release)
www.businesswire.com - September 23 at 3:27 AM
finance.yahoo.com logoEnzo Biochem Schedules Teleconference to Discuss Fourth Quarter 2017 Results Thursday September 28, 2017 at 8:30 AM E.T.
finance.yahoo.com - September 22 at 5:23 PM
thestreet.com logoEnzo Biochem Is Now Oversold (ENZ)
www.thestreet.com - September 19 at 6:20 PM
finance.yahoo.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bullish Manner : ENZ-US : September 1, 2017
finance.yahoo.com - September 1 at 6:40 PM
finance.yahoo.com logoEnzo Biochem, Inc. – Value Analysis (NYSE:ENZ) : August 25, 2017
finance.yahoo.com - August 25 at 7:59 PM
finance.yahoo.com logoEnzo Biochem, Inc. breached its 50 day moving average in a Bearish Manner : ENZ-US : August 17, 2017
finance.yahoo.com - August 17 at 7:31 PM
reuters.com logoBRIEF-Enzo Biochem says federal judge in a U.S. Court has entered an order in action entitled Enzo Life Sciences v. Abbott Laboratories
www.reuters.com - August 16 at 9:03 PM
finance.yahoo.com logoGeron's (GERN) Imetelstat Progressing Well, Setbacks Concern
finance.yahoo.com - August 14 at 6:42 PM
nasdaq.com logoThe Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss
www.nasdaq.com - August 11 at 12:38 AM
finance.yahoo.com logoPerrigo (PRGO) Q2 Earnings & Sales Top, 2017 View Raised
finance.yahoo.com - August 10 at 7:35 PM
finance.yahoo.com logoCatalyst (CPRX) Posts Narrower than Expected Loss in Q2
finance.yahoo.com - August 10 at 7:35 PM
finance.yahoo.com logoOrexigen (OREX) Q2 Loss Narrows, Contrave Sales Impress
finance.yahoo.com - August 9 at 6:28 PM
finance.yahoo.com logoJazz Pharma (JAZZ) Q2 Earnings & Revenues Miss, View Intact
finance.yahoo.com - August 9 at 6:28 PM
finance.yahoo.com logoEpizyme (EPZM) Incurs Narrower-than-Expected Loss in Q2
finance.yahoo.com - August 7 at 6:34 PM
finance.yahoo.com logoJuno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass
finance.yahoo.com - August 4 at 6:33 PM
finance.yahoo.com logoStrongbridge Biopharma (SBBP) Rises: Stock Moves 17% Higher
finance.yahoo.com - August 1 at 6:57 PM
finance.yahoo.com logoDr. Reddy's (RDY) Earnings Decline Y/Y in Q1, Sales Rise
finance.yahoo.com - July 31 at 6:03 PM
marketwatch.com logoImmunoprotein Diagnostic Testing Market Worth $10.3 Billion by 2025: Grand View Research, Inc.
www.marketwatch.com - July 27 at 11:54 PM
nasdaq.com logoBristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View - Nasdaq
www.nasdaq.com - July 27 at 6:51 PM
finance.yahoo.com logoBristol-Myers (BMY) Beats on Q2 Earnings, Tweaks 2017 View
finance.yahoo.com - July 27 at 6:51 PM
finance.yahoo.com logoGlaxoSmithKline (GSK) Beats on Q2 Earnings, Lowers Guidance
finance.yahoo.com - July 27 at 6:51 PM
finance.yahoo.com logoGalapagos (GLPG) Looks Good: Stock Adds 6.2% in Session
finance.yahoo.com - July 21 at 8:14 PM
finance.yahoo.com logoValeant (VRX) To Sell Obagi for $190 Million to Lower Debt
finance.yahoo.com - July 19 at 4:43 PM
finance.yahoo.com logoPerrigo Company Gets FDA Approval for Generic Topical Gel
finance.yahoo.com - July 18 at 7:51 PM
nasdaq.com logoCan Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate ... - Nasdaq
www.nasdaq.com - July 14 at 4:10 PM
finance.yahoo.com logoCan Enzo Biochem (ENZ) Run Higher on Strong Earnings Estimate Revisions?
finance.yahoo.com - July 14 at 4:10 PM
finance.yahoo.com logoGilead (GILD) Application for HIV Drug Validated in EU
finance.yahoo.com - July 14 at 4:10 PM
finance.yahoo.com logo5 Stocks with Recent Price Strength to Enhance Your Returns
finance.yahoo.com - July 13 at 7:40 PM
finance.yahoo.com logoBioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug
finance.yahoo.com - July 13 at 7:40 PM
nasdaq.com logoMallinckrodt to Pay $35M for Controlled Substances Probe - Nasdaq
www.nasdaq.com - July 13 at 12:07 AM
finance.yahoo.com logoRoche (RHHBY) Announces Positive Data on Hemophilia A Drug
finance.yahoo.com - July 11 at 7:28 PM
seekingalpha.com logoEnzo Biochem Rounds The Corner
seekingalpha.com - July 10 at 6:12 PM
finance.yahoo.com logoETFs with exposure to Enzo Biochem, Inc. : July 10, 2017
finance.yahoo.com - July 10 at 6:12 PM
americanbankingnews.com logoHead to Head Review: Enzo Biochem (NYSE:ENZ) vs. NeoGenomics (NEO)
www.americanbankingnews.com - July 1 at 4:04 PM
investopedia.com logoTop 5 Biotech Stocks as of June 2017 (JAZZ, ENZ)
www.investopedia.com - June 14 at 11:07 PM
nasdaq.com logoMid-Afternoon Market Update: NASDAQ Down 2.5%; DuPont Fabros Shares Spike Higher
www.nasdaq.com - June 9 at 5:27 PM

Social

Chart

Enzo Biochem (ENZ) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.